Phoqus Pharmaceuticals nears the end
This article was originally published in Scrip
Executive Summary
Phoqus Pharmaceuticals faces the ignominy of winding down its operations or selling itself after trading of its shares on AIM were suspended. The firm's failure to secure a commercial partner for its lead candidate, Chronocort, preceded the suspension.